item management s discussion and analysis of financial condition and results of operations this discussion and analysis of our financial condition and results of operations contains forward looking statements that involve risks and uncertainties 
we have based these forward looking statements on our current expectations and projections of future events 
such statements reflect our current views with respect to future events and are subject to unknown risks  uncertainty and other factors that may cause results to differ materially from those contemplated in such forward looking statements 
in addition  the following discussion should be read in conjunction with the audited consolidated financial statements and the related notes thereto included elsewhere in this report 
during and through the end of the third quarter of  the company generated revenues from product sales but continues to be dependent upon external financing  interest income  and research and development contracts to pursue its intended business activities 
the company had not been profitable from inception through and has incurred a cumulative net loss of million through december  losses have resulted principally from costs incurred in research activities aimed at identifying and developing the company s product candidates  clinical research studies  the write off of purchased research and development  and general and administrative expenses 
the company expects to incur additional losses over the next several years as the company s research and development and clinical trial programs continue 
the company s ability to achieve profitability is dependent on its ability to develop and obtain regulatory approvals for its product candidates  to enter into agreements for product development and commercialization with strategic corporate partners and contract to develop or acquire the capacity to manufacture and sell its products 
see management s discussion and analysis of financial condition and results of operations liquidity and capital resources 
critical accounting policies the company considers certain accounting policies related to the tax valuation allowance and revenue recognition to be critical policies due to the estimation process involved in each 
revenue the company earns license fees from the transfer of drug candidate technology and the related preclinical research data 
license fee revenue is recognized when all performance obligations are completed and the amounts are considered collectible 
up front license fees are deferred and recognized when all performance obligations are completed 
royalty revenue is recognized upon the sale of the related products  provided the royalty amounts are fixed or determinable and the amounts are considered collectible 
the company has not recognized any royalty revenue during  and tax valuation allowance the company has assessed the future taxable income and has determined that a deferred tax valuation allowance is deemed necessary 
in the event the company were to determine that it would be able to realize its deferred tax asset  an adjustment to the deferred tax asset would increase income in the period such determination is made 
results of operations years ended december  and revenues from sales decreased by  or  from  in to  in the decrease is due to the sale of the company s ophthalmic product line to bausch lomb in october bausch lomb was the company s marketing partner for its ophthalmic product line 
product revenues for the year ended december  included a full year of revenue  while the product revenues for the year ended december  included revenues for only the first three fiscal quarters 
additionally  license fee revenues were  in compared to  in cost of goods sold decreased by  or  from  in to  in the decrease reflects the decrease in product revenue due to the sale of the company s ophthalmic product line to bausch lomb in october cost of goods sold includes the cost of the active drug substance and royalty payments to the licensor 
total operating expenses increased by  or  from  in to  in the increase in operating expenses is primarily due to increased research and development expenses as the company increased expenditures related to the development of dexanabinol for the treatment of traumatic brain injury and to increased activity in the company s cannabinoid program to treat various central nervous system and inflammation based conditions 
the company considers major research development projects to be those projects that have reached at least phase ii level of clinical development 
the only major project of the company is the development of dexanabinol for the treatment of traumatic brain injury  which is currently involved in phase iii testing in europe and israel 
during the periods ending december   and  the costs of this project were million  million and million  respectively 
total costs since the project entered phase ii development in through december  are million 
enrollment in the current phase iii trial is expected to continue until the end of the principal costs of completing the project include patient enrollment  production of the drug product  collection and evaluation of the data  and management of the project 
the primary uncertainties in the completion of the project are the time required to enroll sufficient numbers of patients in the study  the results of the study upon its conclusion  and the company s ability to produce sufficient quantities of drug product under current good manufacturing practice conditions 
should the uncertainties delay completion of the project on the current timetable  the company may experience additional costs that cannot be accurately estimated 
if the phase iii trial of dexanabinol for the treatment of traumatic brain injury is successfully completed  the company can expect to begin to earn revenues upon marketing approval as early as  however  should our product candidate experience set backs or should a product fail to achieve fda approval and market acceptance for any reason  it would have a material adverse affect on our business 
expenses for other research development projects in earlier stages of development for the years ended december   and were million  million and million  respectively 
total research development expenses for the years ended december   and were million  million and million  respectively 
selling  general and administrative expenses decreased by  or  from  in to  in the decrease is primarily due to a reallocation of employee resources to research and development from general and administrative areas 
depreciation and amortization expenses increased by  or  from  in to  in  reflecting increased depreciation expense related to laboratory equipment purchases 
other income expense  net of interest and other expenses  increased by  from expense of  in to income of  in the increase is primarily due to a gain of million from the sale of the company s ophthalmic product line to bausch lomb in october the reported gain includes charges of million representing the company s maximum liability for the completion of the clinical development of le t  the final product resulting from the ophthalmic marketing relationship with bausch lomb 
should le t gain fda approval  the company will receive additional gross proceeds up to a maximum of million depending on the date of fda approval and up to an additional million based upon the achievement of certain sales goals 
also contributing to the increase in other income was a lower level of interest expense primarily due to non cash charges related to the company s convertible debt financing  completed in the third quarter of partially offsetting the increase in other income is decreased interest income as a result of lower market interest rates on the company s cash balances in years ended december  and revenues from sales increased  or  from  in to  in the increase primarily resulted from increased market shares for the company s products 
additionally  license fee revenues were  compared to zero in the license income was primarily generated from the licensing of a technology of the company for use in japan 
cost of goods sold increased  or  from  in to  in the increase reflects the high product revenue for compared to cost of goods sold includes the cost of the active drug substance and royalty payments to the licensor 
cost of goods in grew faster than product revenues as a result of higher expenses for product samples  higher le product license expenses and higher royalties 
total operating expenses increased  or  from  in to  in the increase in operating expenses is primarily due to increases in selling  general administrative expenses  research and development expenses and depreciation 
net research and development expenses increased by  or  from  in to  in the increase in r d expense is primarily due to increased expenditures  including increased employee headcounts  related to the development of dexanabinol for the treatment of traumatic brain injury and to increased activity in the company s cannabinoid program to treat various central nervous system and inflammation based conditions 
selling  general and administrative expenses increased by  or  from  in to  in the increase is primarily due to higher staffing levels and increased investor relations activities 
depreciation and amortization expenses increased by  or  from  in to  in  reflecting increased depreciation expense related to laboratory equipment purchases 
other income expense  net of interest and other expenses  decreased by  from income of  in to expense of  in a higher level of interest expense was primarily due to non cash charges related to the company s convertible debt financing  completed in the third quarter of  of approximately million 
the increased expense was partially offset by increased interest income of approximately million a result of higher average cash balances in liquidity and capital resources while the company received revenues since until the third quarter of from the sale of its approved products  it has incurred cumulative operating losses since its inception and had an accumulated deficit of  at december  the company has financed its operations with public and private offerings of securities  advances and other funding pursuant to a marketing agreement with bausch lomb  research contracts  license fees  royalties and sales  and interest income 
the company had working capital of million as of december  excluding restricted cash of million 
included in the current assets of million is million related to cash and cash equivalents 
in october  bausch lomb purchased all rights to the company s loteprednol etabonate le ophthalmic product line for cash and assumption of certain ongoing obligations 
the company received gross proceeds of approximately million in cash for its rights to lotemax r and alrex r  prescription products that are made and marketed by bausch lomb under a marketing agreement with the company  in addition  bausch lomb also acquired future extensions of le formulations including le t  a product currently in phase iii clinical trial 
the company had no product sales beginning in the fourth quarter of bausch lomb will pay the company up to an additional maximum gross proceeds of million  with the actual payment price based on the date of fda approval of this new combination therapy 
an additional milestone payment of up to million could be paid to the company to the extent sales of the new product exceed an agreed upon forecast in the first two years 
the company has a passive role as a member of a joint committee overseeing the development of le t and has an obligation to bausch lomb to fund up to a maximum of million of the le t development cost 
as a result of this transaction  the company recorded a net gain of million 
the company recorded an accrual of million representing the company s maximum obligation in the continuing clinical development of le t 
the company incurred transaction and royalty costs of approximately million 
the company also compensated the le patent owner approximately million million paid upon closing and million of this amount is to be paid in october from the proceeds of the sale of lotemax and alrex in return for his consent to the company s assignment of its rights under the license agreement to bausch lomb 
additionally  the patent owner will receive of the proceeds payable to the company following fda approval of le t  as well as of its milestone payment  if any 
in september  the company completed a private placement of convertible debentures  common stock and warrants to purchase shares of common stock with institutional investors  generating gross proceeds of million 
the convertible debentures  which generated gross proceeds of million  were due in february and carried a interest payable semiannually in cash or common stock 
in connection with the convertible debenture  the institutional investors also received warrants for the purchase of  common shares with a relative fair value of  the convertible debentures were convertible into common shares of the company at the conversion price of per share or  common shares and were convertible beginning october under certain limited anti dilutive conditions  the conversion price may change 
until converted into common stock or the outstanding principal is repaid  the terms of the convertible debentures require the company to deposit million in an escrow account 
the escrowed capital is shown as restricted cash on the company s balance sheet and will be released to the company in proportion to the amount of convertible debentures converted into common shares or upon the repayment of the debt 
in december  the holders of the convertible debentures and the company agreed to modify the repayment and conversion terms 
the holders of million convertible debt book value on december   including accrued interest extended the maturity date to june in exchange for a reduction in the conversion price from to for half of the outstanding balance and for the other half of the outstanding balance 
the convertible debt with a maturity date of june is convertible beginning december  the holder of the remaining outstanding debt of million including accrued interest changed the maturity date from february  to january  in exchange for lowering the conversion price for the other holders 
as the modification was not significant in accordance with eitf the change in the fair value between the original convertible debt and the modified convertible debt will be accreted over the remaining term of the convertible debt with a corresponding charge into interest expense 
emerging issues task force issue no 
 accounting for convertible securities with beneficial conversion features or contingently adjustable conversion ratios  require the company to compute the beneficial conversion feature bcf of the convertible debt from the private placement of september the bcf must be capitalized and amortized from the closing date until the earliest date that the investors have the right to convert the debt into common shares 
the bcf was computed at approximately million  all of which has been amortized and included as interest expense in the year ending december  additionally  the discount on the convertible debenture of approximately  will be amortized to interest expense over the life of the debt 
for the year ending december    has been amortized 
during  the company paid  and issued  shares of the common stock of the company to the investors in the convertible debenture 
the payment of cash and stock were the option chosen by the company and represent adjustments to the pricing based upon the company s stock price during the adjustment period 
under the terms of the agreements  no further adjustments are due 
one investor in the september private placement had an option  in the form of a warrant  to purchase an additional million of common shares for a period of one year provided that the future purchase price is greater than the initial closing price of per share 
during the third quarter of  the investor exercised this option and  accordingly  the company issued  shares to the investor 
the private placement provided certain conditions under which the number of shares issued for this option could be adjusted and  accordingly  the company issued  shares to the investor in the fourth quarter of as an adjustment to the warrant 
the issuance costs related to the private placement of approximately million were capitalized and amortized over the life of the debt 
for the years ending december  and   and  have been amortized and included as interest expense  respectively 
commitments and long term obligations as of december   we had the following commitments and long term obligations thereafter total operating leases       convertible debentures  excluding interest    r d commitments    grand total       the convertible debenture commitment excludes interest that will accrue until the maturity date in june the principal amount of the debentures plus any accrued interest is convertible into common shares and may ultimately not require a cash outlay 
in january  the convertible debenture commitment of approximately million was repaid in cash 
additionally  million including accrued interest of million was converted into  common shares  thus leaving million including accrued interest of million outstanding as of march  after the repayment and conversion  million was released from restricted cash 
the r d commitments represent scheduled professional fee payments for clinical services relating the phase iii clinical study for dexanabinol 
upon the completion of certain agreed upon milestones  additional fees will be paid 
the fees that pharmos is obligated to pay upon the reaching of the agreed upon milestones is not included in the above table due to uncertainties in timing 
the maximum amount that could be paid is approximately million 
the company has entered into various employment agreements 
the terms of these employment agreements include one year renewable terms and do not represent long term commitments of the company 
management believes that cash and cash equivalents of million and the total restricted cash balance of million as of december   will be sufficient to support the company s continuing operations through at least the middle of the company is continuing to actively pursue various funding options  including additional equity offerings  strategic corporate alliances  business combinations and the establishment of product related research and development limited partnerships  to obtain additional financing to continue the development of its products and bring them to commercial markets 
item a 
quantitative and qualitative disclosure about market risk we assessed our vulnerability to certain market risks  including interest rate risk associated with financial instruments included in cash and cash equivalents  restricted cash  and convertible debentures 
due to the short term nature of the cash and cash equivalent investments  restricted cash  and the fixed interest rate on the convertible debt  we have determined that the risks associated with interest rate fluctuations related to these financial instruments do not pose a material risk to us 

